 |
 |
|
 |
|
|
|
|
 |
FEATURED PRESS RELEASE
-
6/7/13 5:31 am PDTLOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced the initiation of its Phase III clinical trial of the Company's lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease). The Phase III trial will be a randomized trial of PB272 plus Xeloda versus Tykerb plus Xeloda in patients with third-more...
PRESS RELEASES
-
6/5/13 5:31 am PDT
-
5/29/13 5:35 am PDT
|
© Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map |